International Journal of Transpersonal Studies
Volume 33

Issue 2

Article 11

7-1-2014

Psychedelic Experiential Pharmacology: Pioneering Clinical
Explorations with Salvador Roquet (How I Came to All of This:
Ketamine, Admixtures and Adjuvants, Don Juan and Carlos
Castaneda Too): An Interview with Richard Yensen
Philip E. Wolfson
Center for Transformational Psychotherapy

Follow this and additional works at: https://digitalcommons.ciis.edu/ijts-transpersonalstudies
Part of the Philosophy Commons, Psychiatry and Psychology Commons, and the Religion Commons

Recommended Citation
Wolfson, P. E. (2014). Wolfson, P. E. (2014). Psychedelic experiential pharmacology: Pioneering clinical
explorations with Salvador Roquet (How I came to all of this: Ketamine, admixtures and adjuvants, Don
Juan and Carlos Castaneda too): An interview with Richard Yensen. International Journal of
Transpersonal Studies, 33(2), 160–174.. International Journal of Transpersonal Studies, 33 (2).
http://dx.doi.org/10.24972/ijts.2014.33.2.160

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
This Special Topic Article is brought to you for free and open access by International Journal of Transpersonal
Studies. It has been accepted for inclusion in International Journal of Transpersonal Studies by an authorized
administrator. For more information, please contact the editors.

Psychedelic Experiential Pharmacology:
Pioneering Clinical Explorations with Salvador Roquet
(How I Came to All of This: Ketamine, Admixtures and Adjuvants,
Don Juan and Carlos Castaneda Too)

An Interview with Richard Yensen
Philip E. Wolfson
The Center for Transformational Psychotherapy
San Francisco, CA, USA
Richard Yensen was a research fellow at the Maryland Psychiatric Research Center from
1972 to 1976. He studied psychedelic psychotherapy with Stanislav Grof, M.D. and other
senior staff. During this time he treated patients with substance abuse disorders, cancer,
neurosis, and other health professionals seeking a training experience. Dr. Yensen did his
Ph.D. dissertation on the use of MDA in psychotherapy with neurotic outpatients and
conducted his research at the MPRC. Through many years of experience in governmentsanctioned psychedelic research, he has evolved a non-drug shamanistic psychotherapy
called Perceptual Affective Therapy. In the 1990’s Richard was co-holder of IND 3250, an
investigational new drug permit issued by the U.S. Food and Drug Administration to study
LSD and psychotherapy until 2006. He is currently a licensed psychologist in California
and director of the Orenda Institute in Vancouver and Cortes Island, British Columbia,
Canada and president of the Salvador Roquet Psychosynthesis Association. He has served
on the faculties of Harvard Medical School, Johns Hopkins University and the University
of Maryland Medical School in Baltimore.
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Phil Wolfson: Please tell us about your background.
Richard Yensen: I am a Latino at heart and by heritage.
My mother was Panamanian, and I have deep roots in
the soil of America Latina. A portion of my childhood
was spent in the Panamanian isthmus, that bit of land
that connects the two vast continents. There I learned
Spanish and came to a certain sensitivity that would lead
me to a lifelong embrace of Latin culture and people.
This inspired me to bring northern and southern cultures
into an inner amalgam of my own making.
PW: When and where did you become interested in
psychedelic therapy and plant medicine?
RY: The desire to incorporate ancient healing practices
with sacred plants into modern medicine has been a
central passion of mine, as a clinician and psychedelic
researcher, for over forty years. I was first ignited to study
plant medicine during trips to Mexico, a country that
offered me friendship, collegiality, and adventure. Mexico

has been blessed with a wide variety of psychedelic plants
and ancient traditions that have a great deal of healing
potential to contribute to modern psychotherapy.
I have often felt, when visiting the first Nations of
Mexico, as if I were stepping back into ancient times.
The wonder and honor of knowing Maria Sabina, Don
Ricardo, Niuweme, and other healers and shamans, has
transformed my outlook on the practice of psychedelic
medicine.
PW: What role did your contact with indigenous
communities play in unfolding your passion?
RY: My experience among native peoples has taught
me that human beings tend toward a meaning-seeking
and meaning-making journey during their lives. As
individuals, we feel best when we are in touch with our
story, our purpose, our unique nature, and can envision
with some clarity a meaningful path to guide us. It is
truly remarkable that native peoples, from a wide variety
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of indigenous nations within Mexico, are willing to
share the precious keys that open doors to meaning and
belonging, to spirit and wonder. The same people offering
this forgotten wisdom are descendants of those who were
conquered, decimated, and traumatically oppressed by
invaders from Europe.
PW: How do you think the use of plant and psychedelic
medicines relates to healing trauma?
RY: Used wisely, sacred plants and psychedelic drugs can
offer an opportunity for a deep remedial healing experience,
one that repairs despair and annihilates hopelessness with
the most meaningful experiences possible. The effects of
trauma can persist for up to seven generations after the
original insult. Trauma injures the capacity to weave
meaning into our lives, it decontextualizes us, injects a
capricious or diabolical element into our consciousness.
In the course of losing the ability to create meaning, the
individual may well prepare to die of hopelessness, and in
so doing, surrender their cultural and personal histories
the very source of their precious vitality. I have come to
believe that such trauma lies at the core of addiction, posttraumatic stress disorder and some depressions.

peoples of the Amazon were, perhaps the first to
develop an admixture strategy in relation to psychedelic
substances. Their exotic two-plant mixture, called
Ayahuasca, was developed without benefit of any
modern psychopharmacology or laboratory instruments
to monitor purity and without modern understandings
of the nervous system. These pioneers were working
through visionary intuition, guided by the effects of
the different plants they were experimenting with. They
came to the idea that one must take the leaves of a bush
(Psychotria viridis) and combine these leaves with large
chunks of a jungle liana (Banisteriopsis caapi ) and boil
them for hours. Banisteriopsis caapi, the vine or liana
contains a monoamine oxidase (primarily MAO-A)
inhibitor. The properly prepared combination makes this
otherwise inactive combination of plants blossom into a
psychedelic. Ayahuasca has been used for centuries as an
aide to healing (Yensen, 1988). Since the mixture is key to
the presence of the desired effects, rather than a modifier
of already on-going psychedelic effects, this example is
embryonic or prototypical in relation to the subsequent
uses of admixtures in psychedelic psychotherapy.

PW: What are your thoughts on Ayahuasca?
RY: Ayahuasca is an ancient example of the power of
an admixture: in pre-Columbian times the Amerindian

PW: You met Carlos Castaneda while he was still a
student. What do you remember about his debuts as a
best-selling author?
RY: Yes—I met Carlos early on my path, as he was still
“unknown” as a graduate student at UCLA. He had just
published a remarkable little book, Teachings of Don
Juan: A Yaqui Way of Knowledge. My first psychedelic
enchantment was with that little rogue. To me, he
always insisted that his name was pronounced and
spelled Castaneda, not Castañeda.
His subsequent fame and fortune were followed by
academic attack and denouncement. The details of sacred
plant use in Carlos’ books were inaccurate at best. Perhaps
the Yaqui Indian sorcerer/shaman Don Juan may have been
a figment of his imagination. Amidst cries of academic
fraud, Castaneda’s books persisted on the bestseller lists;
his bank accounts grew past the bursting point. This
phenomenal success was all the more remarkable because
with one notable exception (for Time magazine), Carlos
Castaneda did not give interviews to the press, did not
permit portraits, did not make television appearances, and
over all laughed at the antics of journalists and influence
peddlers who pretended to know what was going on in the
world. Efforts to bury the popularity of Carlos Castaneda
and his books remain unsuccessful to this day.
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PW: Do you think native wisdom can help us adapt to
our current planetary challenges?
RY: Absolutely. We live in a world with excessive
environmental stress, collapsing ecosystems, diminishing
cultural diversity, loss of languages and ways of being,
and the dangerous creation of a global monoculture.
At this point in history, it is essential for us to pursue
an awareness of, and openness to, prior successful
adaptations. In order to gain the perspective necessary to
adopt new treatments for trauma, we need to carefully
examine the organization of cultures and societies that
are able to integrate the effects, insights, and experiences
of sacred plants. Indigenous cultures are sophisticated
and elegant in their adaptation to the environment:
their adaptation is, in my opinion, more complete than
our own. The consequences of our poor adaptation
are catching up with us. The pressures of expanding
populations threaten humanity, as we face the same end
story as a colony of bacteria that blindly consumes all
available resources on a petri dish until it collapses.

PW: How do you perceive Carlos Castaneda’s influence
in the West?
RY: Academics focusing on errors and guessing at the
location and tribal identity of the sage in Castaneda’s
accounts ignore the most important aspect of his books,
which is his consummate shamanic act. The details of
sacred plant use in Carlos’s books were inaccurate, and
whether Don Juan actually existed or was a product of
Castaneda’s extraordinary imagination is not even the
point. In his books, Castaneda addressed the children of
those who won World War II and struggled with Korea.
He addressed young men who were being asked to give
their lives in a meaningless war in Southeast Asia. He
captivated the imagination of a generation that grew up
watching cowboys and Indians in movies and television.
He took the well-established sense of cultural superiority,
the illusion of progress and the notion that material plenty
would address all human ills and turned them on their ear.
Through his captivating portrayals of dialogues with Don
Juan, he craftily suggested that this old Yaqui gentlemen
knew something about how to live a meaningful life,
about the inner struggles of being human. He intimated
that overlooked shamanic wisdom could only be had if one
gained membership in another culture. In these accounts,
Carlos himself appears an utter fool and thus portrays
for us the foibles of a person confronting an entirely new
and different worldview. What was most important and
improbable, coming from the cultural darkness of the
fifties, was the worldwide arousal of an entire generation’s
hunger to know these secrets!
In Don Juan’s own terms, Carlos shifted our
assemblage point, the place in our mind where we
construct reality: he shifted his readers out of a semiconscious, culturally self-centered stance. The view that
native people are primitive, dimwitted, helpless and
violent was transformed by Carlos, and replaced by a
sense of mystery, curiosity and wonder. Now, the natives
were suddenly folks who might have the secret of how to
live a life of meaning and profound purpose.
After reading Castaneda’s accounts, I and many
others were influenced to pursue careers in anthropology,
in psychology, in medicine, in literature—often in
pursuit of this hidden knowledge and depth held by
romantic and inaccessible Amerindians. Mexico was
invaded by readers looking for Don Juan, searching for
the Mazatecs, the Huichols and the Tarahumara, trying
to find the lost meaning of their lives. Later, the search
spread to South America.

The effects of the hunger and passion elicited by
Castaneda have been mixed. Ethno-tourism has become
a major industry and is tending to undermine the very
societies it seeks to appreciate. Yet, can we imagine a
greater shamanic success than the complete rending
asunder of the blind conquest of the native peoples of
America? In place of the Conquest, there came to be
an extraordinary, successful restoration of a sense of
wonder and esteem for native people’s nobility, as well
as their botanical, philosophical, and pharmacological
knowledge. He transformed the contemporary children
of the conquerors into determined seekers of native
wisdom. This was his stroke of true mastery, his great
contribution!
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PW: How would you describe the psychedelic therapy
methods that were developed at the Maryland Psychiatric
Research Center in the 1970s?
RY: Experiential psychedelic pharmacology is informed
and guided by the subjective experience of the drug
recipient rather than relying solely on an objective
understanding of drug action. Our psychedelic therapy
technique involved creating the safest, most homelike atmosphere: unthreatening, peaceful and kind, a
completely supportive field within which to administer
a psychedelic drug. Our clinical emphasis was on
encouraging the patient/subject to let go into whatever
experience arose in the drug induced altered state.
Since our patients were utterly safe, unthreatened in the
therapy milieu and relationship, they could be conveyed
toward transcendence with the aide of carefully selected
music (Bonny & Pahnke, 1972). Art was just beginning
to be used as well, to facilitate integration (Kellogg, Mac
Rae, Bonny, & di Leo, 1977). We felt that our approach
would enhance the possibility for the occurrence of a
peak or mystical experience!
It was also likely that patient/subjects might
experience events that could repair emotional wounding
from past life trauma. In our most advanced study
we were involved with a combined psychedelic and
psycholytic technique: cleaning out early emotional
conflicts and difficulty using one to three, sometimes
up to five drug experiences and aiming for a mystical
experience to reintegrate the personality. We were
working with LSD, DPT1, and MDA as adjuncts to
psychotherapy in separate studies. Our ultimate goal was
to create an integrative, healing, and mystical experience
for our patients and subjects.

Our subjects included inpatient alcoholics,
professionals in training, outpatient neurotics, and
terminal cancer patients. We also had a referral program
to which local therapists could refer patients they were
having difficulty treating. The program offered an
opportunity for the referring therapist to become part
of the treatment team, joining with our psychedelic
intervention (Bonny & Pahnke, 1972; Grof, Pahnke,
Kurland, & Goodman, 1971; Kurland, Pahnke,
Unger, Savage, & Goodman, 1968; Kurland, Savage
Pahnke, Grof, & Olsson, 1971; Pahnke, 1963; Pahnke
& Richards, 1966; Pahnke, Kurland, Goodman, &
Richards, 1969a, 1969b; Pahnke, Kurland, Unger,
& Savage, 1970; Pahnke, Kurland, Unger, Savage, &
Grof, 1970, 1971; Pahnke et al., 1970; Tijo, Pahnke, &
Kurland, 1969).
PW: Were drug admixtures commonly used in
psychedelic psychotherapy at the time?
RY: The dawn of psychedelic mixtures in the West
took place in the late 1950s, after clinicians were
already successfully using LSD in psychotherapy (Ling
& Buckman, 1960). Ling and Buckman, in the UK,
observed interesting interactions when they combined
a new drug, labeled as a psychic energizer, with LSD.
Ritalin® or methylphenidate, was the name of this
compound and, at the time, it was available in injectable
form. They administered the drug intravenously to
patients receiving low doses of LSD. They observed that
Ritalin® created a valuable sense of wellbeing in their
patients, similar to the effect of amphetamines.
In the LSD sessions, their patients often
regressed and entered a process that could uncover
traumatic events from childhood. For example, a
difficult memory or one that had been intentionally
forgotten or unconsciously repressed might emerge,
such as a memory of being beaten. In this process the
patient might become frightened and disoriented. They
noted that often patients would project elements of
a scene from the past onto their therapists and/or the
immediate setting. Far too often, their patients became
too frightened to face this emotional flooding. The panic
thus ignited would block the evocative effects of LSD.
As a result, the therapeutic alliance could be diminished
or threatened. But if the therapist administered Ritalin®
at this time, the admixture could foster a sense of
well-being and the patient might realize: “I’m really
okay, even though I feel awful and I’m crying and I’m
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frightened and I’m running away from something.
Whatever it is that I’m avoiding, it’s okay to face it now.
I am safe and in the presence of my doctor who wants to
help me to understand what happened.” The example of
LSD and Ritalin demonstrates the value of a synergetic
mixture: the ability of a drug combination to modify the
emotional experiential quality of an ongoing psychedelic
journey and to facilitate psychotherapy.
In Ling & Buckman’s clinic, an effective
strategy emerged for administering an additional drug
that facilitated their patients feeling sufficiently safe,
thus pharmacologically inducing sufficient safety to face
their most frightening emotions. This ability to bring
insight, catharsis and resolution was a tremendously
valuable innovation in psychotherapy. Ling and
Buckman deemed the discovery worthy of a book (Ling
& Buckman, 1963). Betty Eisner and Hanscarl Leuner
among quite a few other clinicians later incorporated
stimulants as mixtures in their psychotherapy research
and treatment with LSD.
PW: What was your experience with MDA?
RY: In 1967, Claudio Naranjo reported using MDA
as an adjunct to psychotherapy (Naranjo, Shulgin, &
Sargent, 1967; Naranjo, 1973). MDA is a substituted
methylenedioxy-phenethylamine. MDA has some
structural resemblances to both mescaline and
amphetamine, and its subjective properties also seem to
be a blend of the effects of these long-known and longstudied drugs.
Our team at Maryland Psychiatric Research
Center (MPRC) studied the subjective effects of MDA
by administering the drug, in our carefully prepared
psychedelic treatment suites using the techniques we
had perfected for safely conducting LSD sessions. At
that time, the MPRC was the last federal and state
government funded research group doing clinical studies
of the efficacy of psychedelic drugs in psychotherapy.
First we administered MDA to the clinical staff
as a training experience. We found that where LSD
demands internal exploration, MDA seemed to suggest
or invite it. It also tended to foster a sense of wellbeing that was subjectively pleasant and quite useful in
psychotherapy (Turek, Soskin, & Kurland, 1974).
At the Institute, in my own personal MDA
training session, I started out frightened. It was, after
all, my first official psychedelic experience. Then I
became elated as the drug took hold and I transformed
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with it. I noticed that my left hand became freezing
cold, yet my right hand remained warm. I began to
warm my left hand with my right and as I was doing
this self-soothing, I started to recount the story of my
life to the therapists that accompanied me. I recounted
many traumas of my childhood. As I narrated the
memories I felt I was reliving them with only modest
intensity—this included my parents verbal fights and
their subsequent noxious parental events. I continued
comforting myself with my right hand. It occurred to
me that in a sense my hands were illustrating the effect
of the two aspects of the drug action. One side was the
psychedelic—bringing up all this stuff regardless of its
emotional valence without regard for how undesirable
some of the emotions were—the psychedelic brought
forth the traumas and fostered regression. The other side,
the euphoric warm side, brought forward the soothing
sensations. When the experience ended, I felt gratified
at having successfully run a difficult gauntlet to arrive at
my goal—to be on the road to becoming a psychedelic
therapist.
Our research team’s efforts were a molecular
evolution. What began as a clinical technique that
used a 2-drug mixture (LSD & methylphenidate), with
fine control over the exact timing of the second drug
administration and consequently the euphoric effect it
created, was transformed into to a single drug. MDA
was, at that time, the one drug that incorporated two
previously separate functional aspects into a single
molecule that exhibited both subjective qualities2.
Subsequently, I became involved in further
research to assess the use of MDA in individual
psychotherapy with neurotic outpatients and ultimately
used that project for my Ph.D. dissertation. (Yensen,
1975a, 1975b; Yensen et al., 1976).

Roquet was a giant of innovation in
psychotherapy and psychopharmacology, as well as
a physician and high order public health official and
executive in the Mexican ISSSTE3. He was a pioneer
in the development of psychedelic admixtures. He was
among the early explorers of ketamine as an adjunct to
psychotherapy, and he co-discovered ketamine as an
admixture to classical psychedelics in psychotherapy.
PW: What made you feel that you could trust him?
RY: Roquet was a man humble and open enough to ask
native people how they viewed and used their sacred
plants. He not only asked the questions, but took their
answers seriously, even when he was uncertain of the
reasons behind certain principles, like holding mushroom
veladas (vigils) at night rather than in the daytime. He
chose to respect centuries of ritual use and usually opted
for tradition over convenience. He took what he learned
from native healers and combined it with his training as
a Western psychoanalyst in the tradition of Eric Fromm.
Through these wide-ranging sources of inspiration and
his unique awareness as a public health doctor, he forged
a group psychotherapy process that could effectively
address the longing for meaning and connection that is
characteristic of humanity today.

PW: How did you meet Salvador Roquet? What was his
influence in the field of psychedelic psychotherapy at the
time?
RY: I was a research fellow at MPRC in 1973 when
the Clinical Sciences Division received a phone call
from Stanley Krippner, a well-known parapsychology
researcher with interests in psychedelics. Dr. Krippner
had attended the recent World Psychiatry Conference in
Mexico City, where he discovered the work of Salvador
Roquet, a Mexican psychoanalyst. He assured us that
it was imperative that we invite this gentleman to offer
grand rounds at the MPRC.

PW: What was Roquet’s method? How did it differ from
MPRCs?
RY: Whereas our group in Maryland was focused
on scientifically establishing the effectiveness of the
experimental administration of various psychedelic
drugs as adjuncts to psychotherapy, Roquet was freely
combining naturalistic research and experimentation
in consultation with shamanic practitioners with his
unrestricted psychotherapy practice. He told us he had
a blanket permission to use psychedelics that had been
issued through his political connections with the attorney
general’s office of the federal government of Mexico.
In a freewheeling, openly experimental,
naturalistic mode he quickly developed an involved
multi-level poly therapy. He worked with both individual
sessions and group sessions and utilized a wide variety of
psychoactive drugs and plants. Whereas our work was
methodical and linear, he seemed to be doing everything
at once! This was especially striking because our work
had sometimes been criticized for being too multivariate, as we evaluated simultaneous psychotherapy and
drug administration. Any experiment that involves both
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drugs and psychotherapy is far more complex in terms of
careful scientific design and the validation of the results
obtained.
Dr. Roquet practiced a kind of group therapy
he called psychosynthesis4, in groups that ranged from
ten to twenty-eight patients. It was his claim that
through this process he synthesized what most analysts
would analyze. He envisioned his therapy as a roundtrip out of normal consciousness into the world of the
madman and the mystic and then back to normal. He
used a plant delirogen in this approach to produce toxic
psychoses in the course of a multi-session, psychedelic,
transpersonally oriented, therapy. He viewed mystical
experiences as the sine qua non of successful treatment
in this sensory overload setting.
Each group was carefully selected for
composition, balance and heterogeneity, not only
with respect to age and sex but also length of time in
treatment. Patients would receive whatever psychoactive
plant or medicine was prescribed by Roquet, from a wide
variety of possibilities.
Psychosynthesis sessions took place at night,
mirroring shamanic practice in Mexico. Before the
psychoactive session itself, the participants met in a large
room for a leaderless group discussion. This allowed
each patient the opportunity to meet new members
and review his or her expectations, fears, and previous
experiences with the group. An important function
of the pre-drug meeting was to allow projections and
transferences to take place between group members.
There was a self-organizing quality to this therapy
prelude, one that smoothly introduced a new patient
to the process through descriptions from veterans. The
deep candor and openness of these groups set the tone
for what would ensue.
The pre-drug meeting lasted about two hours.
The group then entered the treatment environment,
a large room decorated with an array of paintings and
posters selected for their evocative quality. Toward the
rear of the room there was a large table with a variety of
audiovisual equipment. In the main part of the room,
mattresses were arranged along each wall. The central
part of the room was kept clear so that patients could
walk freely if they wished.
As soon as all the patients entered the room
and settled into their spots, the sensory overload would
begin. The overload used slides, movies, two stereo
sound systems, and colored floodlights that could be

flashed intermittently. The elements included in the
slides and films were as varied as possible. Within
what seemed a confusing barrage of unrelated images
and sounds, there would be a main theme. Among
the themes Roquet found useful were: death, birth,
sexuality, religion, and childhood. Each evening’s
stimuli were assembled so that in addition to the main
theme, there were slides of particular importance for
each client: scenes from childhood, family pictures
and so forth. These pictures, when projected, would be
accompanied by music of importance for that particular
patient. During the overload show, a full-length feature
film with an evocative and conflictual theme was also
projected5. The two stereo sound systems were used with
a wide variety of music from all over the world combined
with sound effects in order to modulate the depth and
intensity of the group’s emotional reactions. When
maximum stimulation was desired a chaotic effect could
be achieved by playing both stereo systems at the same
time at high volume with different records.
After approximately fifteen minutes of
moderately intense sensory stimuli, the psychedelic
substances were administered. The substances used as
therapeutic adjuncts were quite varied, including the
seeds of two types of Morning Glory: Rivea corymbosa
and Ipomea violacea. The outer coat on these seeds has
an emetic effect. The vomiting, combined with a mild
degree of psychedelic action, can facilitate the disruption
of character armor, particularly armoring against
sadness, grief, and involuntary sobbing. This in turn
assisted the recovery of early childhood memories. The
complex reliving of childhood trauma greatly enhanced
the therapeutic alliance and increased trust in the
ongoing therapy process.
In subsequent sessions, any of a variety
of psilocybin containing mushrooms6 could be
administered. In the next session, Lophophora
Williamsii (the Peyote cactus) would be used to
deepen the recollective-analytic process. The deepening
experiences, and emergence of underlying dynamics
related to presenting symptoms, would strengthen the
therapeutic alliance, likely one key among many that
unlocked the success of this therapy.
Finally, Datura ceratocaula (an anticholinergic
delirogen with hyoscyamine, atropine, and scopolamine
as active ingredients), and subsequently, ketamine
hydrochloride (Ketalar®) would be introduced as the last
part of a repeating sequence of psychoactive adjuncts.
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Ketamine was used in three serial intramuscular
injections of 1.5-mg/kg dosage per administration.
Roquet, through consultation with an
anesthesiologist colleague, had discovered that ketamine
in sub-anesthetic doses produced profound changes
in psychological functioning that could be helpful
in his psychotherapy process. One of the important
specific ways that ketamine was useful was to facilitate
reintegration of Datura experiences. Following a Datura
session, overwhelming anxiety was a typical response
to the complete loss of control that occurred due to the
acute psychotomimetic effects of this anticholinergic
plant. Roquet would encourage patients to experience
this anxiety for as long as they could tolerate it between
sessions. Then, in the next session, he would use a triplet
of ketamine administrations in a series to “bring them
out of the Datura.”
The compelling quality of the ketamine
experience would assist his patients in confronting the
conflictual material that presented itself in psychotic
form during the Datura experience. This began the
synthesis aspect of Roquet’s analytic work.
The sensory overload portion of the drug session
lasted for about six hours. After this, pictures from
each patient’s chart were passed out. Bibliotherapy,
psychodrama, and other techniques would be blended
into this multidimensional psychotherapy marathon.
Passages from philosophers might be read by Roquet and
tape recordings of emotional moments from patients’
previous sessions might be played back. This reflective
phase was conducted without sensory overload or music.
Patients might be given letters they had written to
important figures in their life to read aloud for the group.
Other participants might read from their descriptions of
previous sessions or relevant passages from literature.
This phase lasted two to three hours ending around
sunrise. At the end of this phase all participants and the
therapist would sleep or rest for about an hour.
Then, the integrative phase would begin. This
session lasted from four to twelve hours. Each patient
would discuss his or her experience with the group. Greater
abreaction and more intense catharsis than had occurred
during the pharmacological drug peak were characteristic
of this phase. During this session, the personality of
each participant was reintegrated around insights gained
during the drug session. Members of the patient’s family
could visit at this time as the therapeutic milieu expanded
toward the everyday world. The tone of the session was

PW: Did you personally experience ketamine in the
presence of Roquet?
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confrontational, with the therapist presenting patients
with ongoing problems in their life situation. The staff
audiotaped every session for documentary purposes and
for possible use in future sessions.
The course of therapy consisted of ten to fifteen
drug sessions, although as many as twenty could be
necessary for less responsive individuals. The patient
population consisted mostly of neurotic outpatients,
but antisocial personality disorders, character neuroses,
and even schizophrenia were also treated successfully on
occasion.
The contrast between Roquet’s methods and
approach and ours was evident. At MPRC, we occupied
a multi-million dollar facility and conducted fairly linear
clinical studies in a very focused manner according to
rigorous scientific method. Suddenly we were confronted
with Dr. Roquet, a single clinician, doing a much more
complex treatment in an immediately relevant therapy7
using innovative techniques we had never heard of
before. He appeared to be breaking many of the rules
established for successful psychedelic therapy, and yet
he was reporting and illustrating remarkable results.
For example, the fact that the staff wore white coats in a
psychosynthesis session seemed directly at odds with our
home-like atmosphere where therapist and nurse wore
informal street attire.
PW: How did the MPRC staff respond to Roquet’s methods?
RY: There was shock, denial, and disbelief on the part
of many researchers at the MPRC. We had never heard
of such procedures. We had never heard of ketamine.
Dr. Roquet showed artwork created by his patients
during and after the therapy process. Some of these
folks were professional artists of enormous skill and
accomplishment. Slides of these world-class pictures
depicted all aspects of the psychedelic mindscape–from
mystical resolution of major life conflicts, to provocative
cartoons illustrating sexual conflicts. There were intricate
multi-layered oil paintings of spiral galaxies, one with
a gossamer depiction of a blissful embryo radiating
from white light, shining through from behind a huge
crashing breaker at the shore. The art was stunning and
clearly represented deep emotional and transpersonal
experiences as well as the artists’ remarkable skill and
acumen.

RY: Absolutely. On a memorable evening, the head of our
department joined me and a young medical student to
experience the effects of ketamine firsthand. As far as we
knew, at that time, we were the first in the USA to have
the experience of ketamine intentionally administered as
a psychedelic drug rather than an anesthetic.
I was concerned as Roquet injected our chief
with this, until then, unknown psychedelic drug. Usually
poised and thoughtful, almost contemplative, our leader
was blithering. He made repeated, high-pitched, staccato
sounds, rather like stuttering, except the utterances were
complete gibberish. One of the most brilliant individuals
I ever met was suddenly behaving rather like the village
idiot! My own thoughts turned paranoid, “Is this guy
trying to hurt us? What’s happening here?” And just
then, Roquet gave me an injection! Within three minutes
it felt like a cosmic wringer washer had painlessly caught
my little finger. With increasing speed I was wrung out of
my body and out of my paranoid thoughts. I was melted
through the floor of the session room! Actually I melted
out of the room and into the universe, where I became
a spiral arm in a galaxy. Then, I slowly came back to the
room. These transformations were simply stunning, so
much more than anything I’d ever experienced. And at
the same time, they were so matter-of-fact, because the
effects of ketamine were totally compelling. The drug’s
effects overwhelmed me. It was not polite . . . it didn’t
ask: “Would you like to go this way?” but rather it was:
“Here we go!” Out and back in about an hour.
PW: What is it about ketamine that makes it a potent
adjunct to psychotherapy? How was Roquet capitalizing
on those effects?
RY: The two ways Roquet was using ketamine at the time I
first encountered him in 1973 were: 1) as a major psychedelic
experience in its own right, and 2) as the resolving and
grounding agent in a series of other sessions. He had been
using it in a step-wise series, three administrations over a
24-hour group process were considered to constitute one
session. Some of his approach, especially the use of Datura,
had been derived from knowledge gathered through
contact with indigenous healers and shamans. He would
blend this traditional indigenous knowledge with his own
elements, such as the use of ketamine (contemporary)
following a Datura (indigenous) session.
Ketamine has a quality that might best be
conveyed by personifying it, as though the effects of
ketamine are saying, “Take my hand and gently but
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firmly let’s go out of your body.” The journey can be
gentle, but is absolutely definite—there is no way to
resist and in fact resistance is not usually a thought.
Now, free of corporeal restraints and identifications,
there is apparently no limit to where the mind may
wander! “You are going to do this!”
Through this process, patients in Roquet’s
psychosynthesis would begin their journey of
understanding. The ketamine session would follow a
Datura-provoked toxic psychosis in a prior session (a
month earlier). I will carry my personification into the
inner dialogue of the patient, “So that was the whole
process! That is what the hallucination was referring
to, that is why life was so frightening.” Having lost
any semblance of sanity through the effects of Datura,
now this other substance would begin a process of
confrontation, cathartic release and reintegration into a
more insightful sense of self.
Roquet used ketamine to foster a synthesis of
the raw elements that arose in the Datura session. He
likened the effects of the Datura to a steam shovel. This
shovel dug through the mind rather than the earth. It
dredged up repressed conflicts from the unconscious.
The repressed material was experienced in psychotic
hallucinatory episodes. There would be huge amounts of
fear and anxiety when the patient realized that they had
been completely out of control, totally insane under the
effects of the Datura! After a month of anguish or when
the state was absolutely unbearable, ketamine was given.
The ketamine journey fostered insight that the chaotic
Datura experience was not simply crazy. The drug effects
said, “No postponing this one, let’s have a look at it right
now! You, come with me!” The process with ketamine
could also take on a symbolic quality, but usually more
refined than the strange journey with Datura, one
more likely to flow toward a conclusion. With sufficient
resolution of some of their conflicts a patient could survive
to the next psychedelic session without overwhelming
anxiety or depression8. The task of further insight and
integration would then continue with a series of monthly
sessions with ‘classical’ psychedelics: mescaline from
peyote, LSD, psilocybin mushrooms, and morning glory
seeds (amides of lysergic acid).
PW: What do you know about the pharmaceutical
background and current use of ketamine?
RY: Ketamine was originally developed by Parke-Davis
(a subsidiary of Pfizer) as a dissociative anesthetic in the
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1960s and marketed as Ketalar®. Ketamine was developed
in response to complaints from anesthesiologists
about “emergence reactions” when using their premier
dissociative anesthetic product, phencyclidine, which
was marketed as Sernyl®.
Fifty years later, ketamine has become the
hot emerging medicine in psychiatry. Recent reports
of virtually instantaneous anti-depressant effects have
cast ketamine as the holy grail of anti-depressant
development. A major drawback for pharmacologically
oriented clinicians is that ketamine, at sub-anesthetic
doses, can still exhibit psychedelic effects9. This
historical review of psychedelic mixtures and ketamine
will clarify the potential of ketamine as a medicine for
psychedelic psychotherapy rather than as a conventional
pharmacological antidepressant.
PW: What are the psychodynamic effects of ketamine?
How do they affect one’s worldview?
RY: Over the years 1973 to 1975, as I got to know Roquet
more deeply, we began to speak in more detail about
what ketamine actually does on an experiential and
psychodynamic level. I was enthralled that ketamine
helps you out of your body, so that you experience
consciousness without a body. You begin to realize
that it’s possible to have a conscious experience with no
body. This subjective experience is often exhilarating.
The psychological, philosophical and ontological
consequences of such an experience are profound in
terms of their effect on worldview.
I mentioned to Roquet that Freud held that
the ego is, first and foremost, a body ego. Wilhelm
Reich was Freud’s first colleague in charge of
training. As a young psychiatrist he was the analyst
in charge of training for the Vienna Circle. Reich
noticed that as humans grow up, we develop a style of
being. This style of being is character and it’s based
on our reaction to the supportive and noxious events
in our early environment. So, if our parents would
beat us every time we reached for the matches then
we learned not to grasp. Perhaps we would cringe
inwardly when our curiosity was aroused in later
life. The defensive stance toward early trauma, the
desperate survival measures taken to protect oneself,
become part of who we are, part of our character
through repetition. Character is that set of repeatable
and predictable responses that allow us to know a
person through their behavioral repertoire. Ketamine

affects character, by taking people out of their body
and out of their body-armor. Reich realized that
character armor was not just a mental set of defenses,
but a set of chronic tensions in the body that affect
posture and stance (Reich, 1980).
PW: Did you ever try mixing ketamine with other drugs,
besides those that Roquet was already using?
RY: We spoke of what innovations might be possible,
given the enormous freedom with which Roquet was
able to practice at that time. We began to discuss the idea
of combining drugs and I described Ling & Buckman’s
work. As our dialogue continued, I wondered, “What
would happen if we gave ketamine as a prelude to LSD?”
The experience would take the patient out of their armor
and then the LSD would take effect in a pre-conditioned,
more permeable and open psyche. The chance for a
deeper response would be enhanced. The ability to more
fully enter, surrender and stay with an experience might
be fostered by this combination. We agreed that timing
might prove as important with ketamine as it had when
Ling & Buckman were using Ritalin®.
Roquet wanted me to immediately inject him
with a dose of ketamine and then give him LSD. I was
cautious and concerned about possible complications.
Roquet was a diabetic and, to me at that time, his
55 years represented close to old age! His physique
resembled that of a Kwashiorkor victim due to his
distended abdomen. His slightly bowed legs suggested a
history of malnutrition. So, instead I experimented with
myself as the subject by having a colleague administer
ketamine and LSD at the same time. The rationale was
that ketamine would take effect in a minute or so after
an intramuscular injection. The LSD would take roughly
20 minutes to have an effect. I had not counted on the
speed with which sub-lingual LSD could be absorbed.
My experience was that both compounds took effect
in a quick sequence, much closer together than I had
imagined they would.
The effects of the two compounds were
synergistic, each enhancing the effect of the other, but
completely beyond our imagining. I had an extraordinary
experience that took me deeper into altered consciousness
than I had ever been. The ego death was so convincing
that I became certain the mixture was toxic and feared I
had unintentionally administered a fatal combination.
Ketamine fosters emotional release when the
patient/subject is struggling with the containment of
emotional discharge in a major psychedelic experience

168 International Journal of Transpersonal Studies

Wolfson

or ego death. Ketamine assists in the softening and
surrendering of the usual tonic set of energetic and
connective tissue correlating to specific character body
holding. The softening occurs in this practiced habitual
set of muscular constrictions developed as a reaction to
past insults to personal integrity; these were held in place
by fear of death, suffering, and annihilation.
Subsequently, we tried other sequences and
timing, and slowly developed a technique of using
ketamine with other major psychedelics—in sessions
with LSD, mescaline, or psilocybin. The ketamine was
injected at a time when the patient was past the peak
of the effects of the long acting psychedelic, maybe past
some order of an ego death, surrender, and transcendence.
Ketamine would be given at a time when the
ego was reestablishing itself, in a phase where childhood
memories might be accessible and emotional conflicts
might be activated. The patient might be having a little
trouble or they might have opened their heart a lot and
now were closing down on the vulnerability. This can be
observed in the body, in movement and by direct verbal
inquiry, because at this point in the session the person is
oriented enough to be able to speak with you. They can
recount a little bit of what’s happened.

The goal of this process is to reopen the
sensitivity and sensibility of the individual, to reinstate
their vulnerability and their openness and their love.
Their humanity is, in this way, rescued from beneath
their character armor. It is the emotional armor that
restricts affect, restricts expression, restricts the love they
can give themselves and others. Habitual defenses are
melted, as consciousness is dissociated from the body.
Without the psychophysical restraint of rigid character
armor the experiential horizon expands and brims with
all kinds of possibilities.
This collaboration with Roquet added a third
technique to his prior methods for using ketamine in
psychotherapy. I call this the Roquet-Yensen procedure.
Administering ketamine as an admixture toward the
end of a major psychedelic session is perhaps the best
use of this drug in my experience, as it can foster the
most dramatic changes in character, and also ease the
difficulties that can follow complex reliving of traumatic
memories.
After our discovery of the synergism between
ketamine and classical psychedelics Roquet went on
to many years of practice using this, safer and more
manageable approach, in preference to the use of Datura
as a conduit to psychosis.

PW: What makes ketamine an effective adjunct to other
psychedelics like LSD?
RY: When ketamine is administered, it immediately
imposes an out of the body experience, and this disrupts
the return to the ordinary self. It disrupts the assertion
of bodily tensions that constitute character armor, so that
they cannot tighten up in the ways they were tight before
and cannot hold back emotionally in the ways they were
holding back before, or at least not as quickly as they
would otherwise. Ketamine takes patients out of their
body orientation and they are opened again; then many
of the feelings behind the armoring can come pouring
out with a softening, cathartic release and the upwelling
of deeply held emotion.
When patients start coming back from the
ketamine admixture, sometimes they may start closing
down again. If you observe them closing down again,
you can give them a second ketamine injection, and they
will go out again. We found it feasible to give them up
to three ketamine sessions during the tail of diminishing
LSD effects. We used a setting and timing that was ample
enough so as to have a 24-hour therapeutic window for
working with the person in psychotherapy.

PW: How was Roquet perceived in Mexico? What
happened to him after the changes of climate in Mexican
politics in the 1970s?
RY: Roquet was quite a character. On the one hand, he
was admired as a lone clinician heading up a non-profit
institute, with a multifaceted approach to effectively
address human suffering. There were many unique parts
to his offering. At his Institute there was a Summerhill10
inspired primary school for children. Additionally,
another school taught how to be an effective parent. The
psychiatry clinic, in effect, taught how to live a loving
and full life. Indeed, Roquet seemed larger than life,
resembling some of his heroes, a combination of Albert
Schweitzer and Mother Theresa.
However, he was also, and undisputedly, a
controversial figure. He shared wild exploits ranging
from his ethically questionable participation in
psychedelic interrogation by the Federal Police, to
giving a young revolutionary named Mario Falcon
a therapeutic psychedelic experience that convinced
him to surrender, in the midst of the subsequent, nonviolent student protest and occupation of the University
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of Mexico—UNAM. That non-violent occupation
resulted in the murder of as many as 300 students and
civilians by the Mexican police, which has come to be
known as the Tlatelolco Massacre. Falcon subsequently
decided to emigrate to Chile and become an artist.
Roquet negotiated his release. Roquet’s participation
remains controversial and for some stained his reputation
in Mexico.
Robert S. Hartman, the well-known philosopher
and axiologist from University of Tennessee and UNAM,
described the work at Roquet’s Institute as meaning
making of the highest intrinsic order. This was not
entirely realized by the Mexican Constabulary. Roquet’s
benefactor at the Department of Justice (Procuraduria),
the originator of his “blanket” permission to practice
psychosynthesis with psychedelics, had presidential
ambitions in the forthcoming election. Soon, the winds
of fate changed direction. Roquet knew it was coming
and thought he had accepted his fate.
The headline that led to Roquet’s arrest was,
“24 hours in Hell.” The article appeared in the popular
magazine Tiempo. It was part of a carefully orchestrated
press blitz designed to discredit him and portray his work
in the most outrageous way. The journalist, the author of
the article, was so terrified in his psychosynthesis session
that he locked himself in the bathroom the entire time!
The federales burst into the institute expecting
to catch the doctor dispensing the prohibited elixirs of
freedom, the condemned sacred plants, sacraments to
the first people in this land. When the Conquistadors
arrived in the New World full of the Spanish Inquisition,
they brought with them the mysterious un-healing evil
wounds of trauma. There was no tolerance for direct
experience of the sacred. They preferred symbols of spirit
mediated through corrupt priests deeply involved with
power and royalty. That first horse of the Apocalypse,
who initially waded ashore in the New World disguised
as a Conquistador, now arrived in the form of a Federale,
policeman of the Federal District of Mexico.
After his arrest, Roquet was interrogated in the
room in which he had interrogated others. He knew of
the existence and the location of the two-way glass but
that made the dismantling of his identity perhaps more
brutal. He was broken completely!
They imprisoned him in a former palace called
Lecumberri, then transformed into an inescapable
prison. Its history is somehow fitting for a country of
such passion and struggle, as is Mexico. The sprawling

building that was at once magnificent and humiliating
represented the power of the state to annihilate the gift
of freedom that is life, to incarcerate those who would
dare to challenge the ultimate authority and reign of the
great static archetype of government. This palace turned
penitentiary had an illustrious list of unwilling tenants
that included the great revolutionary Pancho Villa
and the impassioned muralist David Alfaro Siqueiros.
Jaime Ramón Mercader del Río Hernández, murderer
of Leon Trotsky, had lingered there after his famous
act of assassination. Only the prominent revolutionary
general, Pancho Villa had ever escaped the clutches of
this enslaving dungeon alive. No wonder they called it
The Black Palace of Lecumberri! The powerful tendrils
of royalist domination contained those yearning
revolutionary urges to liberation more effectively that
day than they did in the time of Pancho Villa.
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PW: How did you react to Roquet’s persecution?
RY: Roquet and I shared a vital wound throughout our
lives. Both of us had been abandoned by our fathers at
birth. We danced a transferential tango in our emotional
relationship. I was both his father and his son and he
mine. I was his LSD guide in training sessions at the
Maryland Center; he was mine in sessions when I visited
him in Mexico. We felt admired, loved, acknowledged,
and abandoned by each other throughout 22 years of
more of collegial friendship.
At the time of his imprisonment, I was only
23 years old and a Ph.D. candidate, but I had to set
him free! His defense team had told me that the key
to success was humiliation of those who condemned
him. Letters from world famous people, powerful icons
from abroad, would immeasurably aid his case. I raced
to Mexico City to testify before the House of Deputies
and the Supreme Court. I brought with me two
psychiatrists, Kenneth Godfrey and James Davis. Dr.
Godfrey was a well-established psychedelic researcher
at the Veterans Administration Hospitals, and he bore
a letter of support from perhaps the most illustrious
psychiatrist in the USA, Dr. Karl Menninger, who was
co-founder of the famous Menninger Clinic in Topeka,
Kansas. Dr. Davis was co-founder of the fledgling Davis
Psychiatric Clinic in Indianapolis, Indiana. He came
to describe how impressed he and his U.S. Air Forcetrained psychiatrist brother Larry were with Roquet’s
therapy process. Dr. Walter Houston Clark, psychologist
of religion, also joined us in the struggle to liberate this

pioneer of psychedelic medicine from the clutches of
denouncing political expediency. The administration of
my own Maryland Psychiatric Research Center was not
willing to risk the political consequences of supporting
Roquet against the gathering forces of the great wave of
prohibition, although he was one of our LSD professional
training program participants.
A U.S. born lawyer practicing in Mexico City
told me that the CIA had approached Roquet about
“treating” a few special patients for them. If he would
turn his art once again to interrogation, as he had been
willing to do for the Mexican government at one point,
the U.S. spy agency would establish a clinic where he
could practice as freely in the U.S. as he had in Mexico.
Roquet turned them down, and they began fueling
the process that led to his arrest and imprisonment
as a political football in the forthcoming presidential
election.
PW: There is something about Salvador Roquet that
brings to mind Carlos Castaneda. Do you see any
parallels between these two figures?
RY: Roquet was charismatic in his actions, commanding
and compelling in his therapy. Carlos Castaneda was
charismatic and compelling in his writing. The sticking
point for both was charisma, the illusive and compelling
quality that completely seduces followers. The charm
that completely seduces the place in each of us that
wants to be led by a superior individual. A double-edged
sword, charisma can be a tremendously positive quality.
Certainly these two men would not have occupied
the place they occupy in history were it not for their
charismatic qualities. Yet, in a way, the undoing of each
of them was precipitated by their charisma, by their
compelling popularity with some, and by the jealousy
that that engendered in others.

very valuable. Yet, what I have described in terms of
ketamine’s psychedelic effects is both so complicated and
so advanced that we do not have, as yet, an appropriate
way to measure what is actually happening. We are
getting closer to that with recent work by Robin Carhart
Harris and David Nutt in the UK with brain scans and
magneto encephalography (MEGs; Carhart-Harris &
Friston, 2010; Carhart-Harris et al., 2012).
It will take us many years in our over regulated,
drug war inhibited, logical scientific approach, to be
able to develop complex and integrated approaches as
Roquet and I were able to do with the clinical freedom
he briefly enjoyed. All good things come to an end, and
even he was beset with legal problems and imprisonment
later in his career. Subsequent legal victories and
clinical vindication were unable to reinstate his unique
permissions and freedom to practice. I was privileged
to have known and worked with Salvador Roquet. His
life and unique practice have left an indelible mark on
psychedelic psychotherapy, and on the broad notion of
what is psychotherapy. There are many contemporary
practitioners who remain influenced by him and he is an
enduring part of the work that continues to attempt to
understand and benefit humans and their relationships.
Notes

PW: Do you foresee any hope of continuing the project
of investigating ketamine’s potentials for expanding
consciousness and healing?
RY: Currently, ketamine is being studied as an instant
antidepressant (Maeng & Zarate, 2007; Maeng et al.,
2008; Aan Het Rot, Zarate, Charney, & Mathews,
2012; Laje et al., 2012). Researchers have isolated the
antidepressant effects they have observed, and are
attempting to engineer molecules that will separate
antidepressant effects from psychedelic effects. Having
a new source of powerful antidepressants is, of course,

1.    Dipropyltryptamine had a variable duration of
action, approximately one hour in low doses
(psycholytic doses) and four to six hours in higher
doses (psychedelic doses).
2. When in the 1980s a compound with less prominent
psychedelic effects and more prominent euphoria
was revealed, MDMA emerged as a promising
psychotherapy adjunct (Greer & Strassman, 1985)
3. Instituto de Seguridad y Servicios Sociales de los
Trabajadores del Estado, Institute of Social Services
and Safety for the Workers of the State.
4. Although psychosynthesis is better known as an
approach to transpersonal psychotherapy pioneered
by Roberto Assogioli in Italy, Roquet’s approach
was independently developed and is an absolutely
unique style of therapy. The only commonality is
the name.
5.   For instance, The Bird Man of Alcatraz was one of
the films used on occasion, for its dramatic portrayal
of an Oedipal theme concerning the protagonist’s
relationship with his mother.
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6. Psilocybe Mexicana, Psilocybe Mazatecorum,
Psilocybe cubensis for example.
7. Roquet had around 300 patients engaged in his
process at any given time.
8. I introduced Salvador Roquet to Richard Evans
Schultes, the intrepid Harvard botanist who
documented so many psychedelic plants in the
Amazon during WWII. When I mentioned the
use of morning glories and Datura, Schultes was
immediately animated and enthused in his response,
“What a wonderful idea! Perhaps when the Aztecs
referred to the Ololiuqui (Rivea corymbosa) as the
sister of Datura they were referring to more than a
floral resemblance. He found it fascinating that they
could be kept or used together. He also mentioned
that Datura is a common admixture to Ayahuasca
prepared by shamans in the Amazon.
9. These are referred to as emergence reactions in the
anesthesia literature and Parke-Davis admitted
that 12.5% of patients reported this after ketamine
anesthesia.
10.    
Summerhill School is an independent British
boarding school that was founded in 1921 by
Alexander Sutherland Neill in the belief that the
school should be made to fit the child, rather than
the other way around.
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